Payment overview · 2025
General Payments
$706.30
21 reported records · 11 companies
Healthcare provider profile · identity verified
Sanjay Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, NJ · NPI 1437120920
Verified facts
What the public records show
CMS Open Payments records show Sanjay Kumar, MD received $706.30 in general payments during 2025 across 21 reported records.
Abbott Laboratories accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $160.01 | 22.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $156.84 | 22.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.30 | 17.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $98.43 | 13.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.60 | 10.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.77 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.96 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.68 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.53 | 2.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.71 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.47 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $706.30 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $160.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $156.84 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $120.30 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $98.43 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.60 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 840 | 185 |
| Eliquis | Apixaban | 560 | 82 |
| Gabapentin | Gabapentin | 517 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 110 |
| Furosemide | Furosemide | 338 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 324 | 78 |
| Losartan Potassium | Losartan Potassium | 321 | 73 |
| Potassium Chloride | Potassium Chloride | 292 | 62 |
| Metformin Hcl | Metformin Hcl | 250 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 54 |
| Famotidine | Famotidine | 235 | 48 |
| Lisinopril | Lisinopril | 235 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 230 | 45 |
| Sertraline Hcl | Sertraline Hcl | 215 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 194 | 29 |
| Omeprazole | Omeprazole | 161 | 33 |
| Mirtazapine | Mirtazapine | 157 | 35 |
| Simvastatin | Simvastatin | 153 | 27 |
| Prednisone | Prednisone | 152 | 69 |
| Xarelto | Rivaroxaban | 150 | 28 |
| Carvedilol | Carvedilol | 148 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 139 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 36 |
| Levetiracetam | Levetiracetam | 133 | 21 |
| Divalproex Sodium | Divalproex Sodium | 132 | 27 |
| Januvia | Sitagliptin Phosphate | 127 | 13 |
| Trazodone Hcl | Trazodone Hcl | 126 | 34 |
| Donepezil Hcl | Donepezil Hcl | 118 | 25 |
| Jardiance | Empagliflozin | 118 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 48 |
| Alprazolam | Alprazolam | 115 | 33 |
| Tramadol Hcl | Tramadol Hcl | 109 | 40 |
| Midodrine Hcl | Midodrine Hcl | 108 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 32 |
| Montelukast Sodium | Montelukast Sodium | 98 | 25 |
| Allopurinol | Allopurinol | 89 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 23 |
| Metformin Hcl Er | Metformin Hcl | 86 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 75 |
| Digoxin | Digoxin | 83 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 20 |
| Nifedipine Er | Nifedipine | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 22 |
| Azithromycin | Azithromycin | 73 | 63 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 15 |
| Ezetimibe | Ezetimibe | 73 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 25 |
| Spironolactone | Spironolactone | 71 | 21 |
| Finasteride | Finasteride | 70 | 14 |
| Torsemide | Torsemide | 70 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 38 |
| Ranolazine Er | Ranolazine | 67 | suppressed |
| Valsartan | Valsartan | 63 | 18 |
| Buspirone Hcl | Buspirone Hcl | 62 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 31 |
| Clonazepam | Clonazepam | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 24 |
| Lactulose | Lactulose | 60 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 11 |
| Latanoprost | Latanoprost | 57 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 13 |
| Atenolol | Atenolol | 54 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 54 | 16 |
| Bumetanide | Bumetanide | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 11 |
| Baclofen | Baclofen | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 24 |
| Nystatin | Nystatin | 50 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 15 |
| Cephalexin | Cephalexin | 49 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | 19 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | 12 |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 43 | 12 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Procrit | Epoetin Alfa | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Epogen | Epoetin Alfa | 40 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 31 |
| Colchicine | Colchicine | 39 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 39 | 15 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 22 |
| Levofloxacin | Levofloxacin | 37 | 25 |
| Oxcarbazepine | Oxcarbazepine | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 12 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Repaglinide | Repaglinide | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 24 |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 17 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 31 | suppressed |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 12 |
| Santyl | Collagenase Clostridium Hist. | 25 | 14 |
| Vancomycin Hcl | Vancomycin Hcl | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Daptomycin | Daptomycin | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystop | Nystatin | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clozapine Odt | Clozapine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Atacand | Candesartan Cilexetil | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Desoximetasone | Desoximetasone | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $706.30 · 21 records | Abbott Laboratories | AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, KISUNLA, Kerendia, Korlym, REXULTI, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error